Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Hsieh

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
The Journal of Biological Chemistry|February 15, 2011
Transient-state kinetic analysis of transcriptional activator·DNA complexes interacting with a key coactivatorAmberlyn M Wands, Ningkun Wang, Jenifer K Lum, et al.
RNA (New York, N.Y.)|April 19, 2006
Functional characterization of the conserved amino acids in Pop1p, the largest common protein subunit of yeast RNases P and MRPShaohua Xiao, John Hsieh, Rebecca L Nugent, et al.
RNA (New York, N.Y.)|February 15, 2007
Probing the architecture of the B. subtilis RNase P holoenzyme active site by cross-linking and affinity cleavageSomashekarappa Niranjanakumari, Jeremy J Day-Storms, Mahiuddin Ahmed, et al.
JCI Insight|April 9, 2026
Pharmacological PIK3C2B inhibition rescues XLMTM phenotype in mouse models and identifies molecular markers of diseaseAndrew Shearer, Melissa L Brooks, Maxine M Chen, et al.
The Journal of Organic Chemistry|May 5, 2007
A photoactive isoprenoid diphosphate analogue containing a stable phosphonate linkage: synthesis and biochemical studies with prenyltransferasesAmanda J DeGraw, Zongbao Zhao, Corey L Strickland, et al.
Therapeutic Advances in Medical Oncology|October 24, 2024
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancerSun Min Lim, Stefanie S Schalm, Eun Ji Lee, et al.
Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.
Journal of Medicinal Chemistry|July 15, 2022
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung CancerMeredith S Eno, Jason D Brubaker, John E Campbell, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
The Journal of Biological Chemistry|February 15, 2011
Transient-state kinetic analysis of transcriptional activator·DNA complexes interacting with a key coactivatorAmberlyn M Wands, Ningkun Wang, Jenifer K Lum, et al.
RNA (New York, N.Y.)|April 19, 2006
Functional characterization of the conserved amino acids in Pop1p, the largest common protein subunit of yeast RNases P and MRPShaohua Xiao, John Hsieh, Rebecca L Nugent, et al.
RNA (New York, N.Y.)|February 15, 2007
Probing the architecture of the B. subtilis RNase P holoenzyme active site by cross-linking and affinity cleavageSomashekarappa Niranjanakumari, Jeremy J Day-Storms, Mahiuddin Ahmed, et al.
JCI Insight|April 9, 2026
Pharmacological PIK3C2B inhibition rescues XLMTM phenotype in mouse models and identifies molecular markers of diseaseAndrew Shearer, Melissa L Brooks, Maxine M Chen, et al.
The Journal of Organic Chemistry|May 5, 2007
A photoactive isoprenoid diphosphate analogue containing a stable phosphonate linkage: synthesis and biochemical studies with prenyltransferasesAmanda J DeGraw, Zongbao Zhao, Corey L Strickland, et al.
Therapeutic Advances in Medical Oncology|October 24, 2024
BLU-945, a potent and selective next-generation EGFR TKI, has antitumor activity in models of osimertinib-resistant non-small-cell lung cancerSun Min Lim, Stefanie S Schalm, Eun Ji Lee, et al.
Molecular Cancer Therapeutics|May 13, 2026
BLU-451, a CNS-Active, Potent, and Selective Small-Molecule Inhibitor Against Uncommon EGFR MutationsYves A Millet, Alexander I Spira, Christina S Baik, et al.
Journal of Medicinal Chemistry|July 15, 2022
Discovery of BLU-945, a Reversible, Potent, and Wild-Type-Sparing Next-Generation EGFR Mutant Inhibitor for Treatment-Resistant Non-Small-Cell Lung CancerMeredith S Eno, Jason D Brubaker, John E Campbell, et al.
Pageof 2